Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Population pharmacokinetics predicts vancomycin empiric dose frequency in acute brain injury

14 Jun 2019

Population pharmacokinetics accurately predicts the empiric dose frequency of vancomycin in patients with acute brain injury, as shown by the small clinical difference in population and patient-specific elimination rate constants, according to a new study.

The analysis included 158 patients (aged 18 years) with acute brain injury. Mean population-predicted elimination rate constant was larger by 0.0211 h−1 (95 percent CI, −0.028 to −0.015) in the test of paired differences between the mean population-predicted and patient-specific elimination rate constants. The difference between the corresponding half-lives showed a 1.01-hour (0.7–1.3) shorter mean population-predicted half-life.

Vancomycin at a mean initial dose of 15.4±2.2 mg/kg, with an average frequency of 12±1.1 hours, was administered. The average trough concentration at steady state was 9.9±4.9 µg/mL.

This single-centre, retrospective cohort study, which was conducted after institutional review board approval at Virginia Commonwealth University Health System, sought to determine whether population pharmacokinetics accurately predicted vancomycin empiric dose frequency in patients with acute brain injury. Data were then obtained from this population.

The difference in the elimination rate constant of vancomycin between population-predicted pharmacokinetics and patient-specific pharmacokinetics was the primary outcome.

“Vancomycin is a glycopeptide antibiotic that is primarily cleared by renal elimination,” the investigators said. “Patients with acute brain injury often exhibit augmented renal clearance which has been associated with subtherapeutic vancomycin concentrations.”

Current guidelines recommend empiric doses of vancomycin 15–20 mg/kg administered by intermittent infusion every 8–12 hours in patients with normal kidney function. In addition, the recommended trough concentration is 15–20 mg/L as a therapeutic goal for adult patients with severe infections. [Eur J Drug Metab Pharmacokinet 2018;43:259-268]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.